Independent Medical Education Grant - Annual Meetings

Overview

Independent Medical Education Grant RFP

Pfizer Global Medical Grants recognizes knowledge exchange as an important component of the continuing education continuum and offers support for these programs through independent medical education grants.

An independent medical education grant is a type of grant which consists of Pfizer funding for independent medical education activities or initiatives which serve to maintain, develop, or increase the knowledge, skills, and/or professional performance of a healthcare professional (e.g. continuing medical education, continuing health education, continuing education). These activities or initiatives may or may not be accredited.

ANNUAL MEETINGS

Eligible organizations can request funding to support LIVE national and regional conferences and congresses.

In order to submit a request for general meeting support for an Annual Meeting, the answers to the following questions must be “Yes”:

* Does the activity align with Pfizer’s Primary Areas of Interest? 
 Is the activity a live\ annual program which serves as a platform for the exchange of new clinical and scientific information and reaches an international, national, regional or local audience?
\Live CME/CE activities are defined as any activity which incorporates the opportunity for live real-time learner interaction, such as live meetings
*  Is the activity an established part of your organization’s ongoing educational program? If not and it is a new activity, is it clearly based on an assessment of the educational needs of your target audience?
*  Is the requested grant amount within the following parameters:
* $50,000 or less for an Annual Meeting with a national/international target audience;
* $25,000 or less for an Annual Meeting with a regional/local target audience?

Eligibility

_We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's [website]().
_

Application Details

2025
Pfizer Global Medical Grants & Partnerships
Annual Meetings: Submission Deadlines, Primary Areas of Interest, & Educational Goals
In order to submit a request for general meeting support for an Annual Meeting, the answers to the following questions must be “Yes”:
Does the activity align with Pfizer’s Primary Areas of Interest? (listed below)
Is the activity a live* annual program which serves as a platform for the exchange of new clinical and scientific information and reaches an
international, national, regional, or local audience?
*Live CME/CE activities are defined as any activity which incorporates the opportunity for live in-person real-time learner interaction.
Virtual-only programs are not in-scope.
Is the activity an established part of your organization’s ongoing educational program? If not and it is a new activity, is it clearly based on
an assessment of the educational needs of your target audience?
Is the requested grant amount within the following parameters: $50,000 or less for an Annual Meeting with a national/international target
audience; $25,000 or less for an Annual Meeting with a regional/local target audience?
To Submit Live Activity Must Decision
Application Cycle Start On or After Communicated By
Jan 1 - Feb 15 April 1 March 18
Mar 1 - Apr 15 July 1 June 3
June 1 - July 15 October 1 August 30
Sept 1 - Oct 15 January 1, 2026 November 27
If your activity is in… Latest* Date to submit to Pfizer is….
April, May, or June 2025 February 15
July, August, or September 2025 April 15
October, November, or December 2025 July 15
January, February, or March 2026 October 15
*This is the latest date to submit. Your request will be reviewed if submitted in an earlier cycle.
Questions? Email GMGP@pfizer.com
Updated February 2025

2025
Pfizer Global Medical Grants & Partnerships
Annual Meetings: Submission Deadlines, Primary Areas of Interest, & Educational Goals
Autoimmune Diseases
Dermatology- Alopecia Areata
For dermatologists and all healthcare professionals involved in the care and treatment of patients suffering from alopecia areata, increase the
awareness and understanding of assessing disease severity, burden of disease, and the use of kinase inhibitors for the treatment of alopecia
areata, including for adolescent patients.
Dermatology- Atopic Dermatitis
Improve the care of patients manifesting atopic dermatitis (AD) by increasing healthcare provider knowledge of the disease state or unmet need
and the emerging strategies for treatment of AD.
Gastroenterology- Inflammatory Bowel Disease (IBD); Gastroenterology-Ulcerative Colitis (UC)
• Improve the care of patients with inflammatory bowel disease (IBD) by increasing healthcare provider of the emerging strategies
for treatment of UC.
• Address healthcare disparities in diagnosis of UC and access to UC care
• Increase provider awareness of multidisciplinary approach and shared decision making in treatment of patients with UC
Inflammation and Immunology - Biosimilars
Increase health care professionals’, regulators’, payers’ and patients’ understanding of complex biosimilar concepts including the
o
analytical foundation for demonstrating biosimilarity and the regulatory science governing the approval of biosimilar drugs
Increase HCP’s confidence in the appropriate use of biologics/biosimilars in treatment plans
o
Improve the ability of healthcare professionals to discuss biosimilar options with their patients as part of shared-decision-making
o
Cardiovascular Metabolic Risk
CVM – Cachexia
Increase the awareness of cancer cachexia including the burden on patients and caregivers with the goal of improving diagnosis and earlier
intervention
CVM – Obesity
Improve the care of patients with obesity by 1) increasing the knowledge of healthcare providers (HCPs) on the pathophysiology of obesity and
its recognition as a disease and 2) elevating awareness of the unmet needs in the treatment of obesity
Questions? Email GMGP@pfizer.com
Updated February 2025

2025
Pfizer Global Medical Grants & Partnerships
Pain- Migraine
Annual Meetings: Submission Deadlines, Primary Areas of Interest, & Educational Goals
To improve the care, management, and outcomes of adult patients with migraine by supporting HCP and patient education on topics including:
• Unmet need and disease burden associated with migraine
• The role of CGRP in the pathophysiology of migraine, as well as safety and efficiency of CGRP treatment
• CGRP receptor antagonists in the acute treatment of migraine and preventive treatment of episodic migraine
• The diagnosis and management of migraine by GPs and specialists (focus on acute treatment and prevention of episodic migraine)
Oncology
Oncology – Breast
For oncologists and all healthcare professionals involved in the care and treatment of patients with breast cancer, increase the awareness and
understanding of the latest emerging research, ongoing clinical trials, and real-world evidence studies, the clinical management of patients with
advanced HR-positive, HER2-negative breast cancer receiving oral therapies, including specific patient populations (e.g. co-morbidities, older
patients), mechanisms of resistance, mechanisms-of-action of new medicines, and advances in CDK 4/6. Other topics of interest include
sequencing strategies, optimizing clinical practice, application of real-world evidence to clinical decision-making, provider-patient shared
decision-making, and implementation of clinical pathways.
Oncology – Gastrointestinal– Colorectal Cancer
increase the understanding of BRAF V600E and HER2+ targeted therapies and their use in the treatment of metastatic colorectal cancer (mCRC)
including:
• Prevalence of HER2+ and BRAF V600E-mutated mCRC
• Incorporating biomarker and genomic testing into community cancer center standard practice
• Incorporating the use of targeted therapies into clinical practice
• Increasing understanding of recent clinical data to help inform the selection of treatment options
• Monitoring for and managing side effects of therapies
Oncology – General – Research Topics
Through the academic exchange of research and ideas, enhance the discovery and translation of novel cancer therapies, increase scientific
understanding of their mechanisms-of-action as well as the efficacy, safety, and potential clinical applicability. Topics of interest include
epigenetic modification, signal transduction, cytotoxic potentiators, tyrosine kinase inhibitors, immunotherapy, biosimilars, antibody drug
conjugates, biomarkers, and immuno-oncology (IO) specific correlates of safety and efficacy. Also, within IO there is particular interest in
advancing the understanding of combinations of novel IO therapies with conventional, antibody drug conjugates, targeted, radiation, and existing
IO therapies.
Questions? Email GMGP@pfizer.com
Updated February 2025

2025
Pfizer Global Medical Grants & Partnerships
Annual Meetings: Submission Deadlines, Primary Areas of Interest, & Educational Goals
Oncology – General - Pediatric Oncology
For pediatric oncologists and all healthcare professionals involved in the care and treatment of pediatric patients with cancer, increase
understanding of the relevant mechanisms-of-action for pediatric cancer and increase awareness of the evolving treatment landscape and
results of clinical trials in order to enhance the application of this information to patient care.
Tumors of interest include pediatric leukemias (ALL, AML, CML, APML, JMML), lymphomas (Hodgkin, non-Hodgkin, ALCL) solid tumors
(osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, Wilm’s tumor/nephroblastoma, retinoblastoma, hepatoblastoma), CNStumors
(medulloblastoma, glioma, astrocytoma, glioblastoma, DIPG), and other rare pediatric tumors. Additional topics of interest in these tumor types
include epigenetic modification, signal transduction, cytotoxic potentiators, tyrosine kinase inhibitors, immunotherapy, antibody drug
conjugates, cellular-based therapies, and biomarkers.
Oncology – Genitourinary – Prostate
Increase understanding of PARP-inhibitor-class in prostate cancer including mechanisms of action in combination with NHTs, and
genetic/biomarker-testing implications for clinical practice.
Increase understanding of:
• differentiated mechanism of action (MOA) of emerging therapies including EZH2 inhibition and its possible role in prostate
cancer
• EZH2 and other novel mechanisms of disease (MOD) and their role in prostate cancer progression
• the investigational thesis of how concomitant EZH2 and AR inhibition may suppress prostate cancer while delaying or overcoming ARPi
resistance
• the continued unmet need for novel therapies in mCRPC
Oncology – Genitourinary – Urothelial Carcinoma (UC)
For oncologists, urologists and other healthcare providers involved in the care and treatment of patients with bladder cancer, increase
understanding of:
• the evolving treatment landscape of first-line metastatic UC including the unmet need in cis-eligible patients and the holistic
management of patients with UC
• early identification and management of adverse events associated with UC treatment within the multidisciplinary team
• the role of ADCs and their targeted MOA as part of addressing the unmet need in earlier stages of UC
Questions? Email GMGP@pfizer.com
Updated February 2025

2025
Pfizer Global Medical Grants & Partnerships
Oncology – Genitourinary – Renal Cell Carcinoma (RCC)
Annual Meetings: Submission Deadlines, Primary Areas of Interest, & Educational Goals
For oncologists, urologists and all healthcare professionals involved in the care and treatment of patients with advanced RCC, increase
awareness of the evolving treatment landscape and clinical trial results, and also improve clinical competence in applying this information to
patient care, especially with respect to treatment selection, sequencing, scheduling, dosing, adjuvant use, use of combination therapies, and
management of side effects.
Oncology – Gynecological – Cervical Cancer
For recurrent/metastatic cervical cancer (r/m CC), with focus on HCP and care team members managing patients in the community practice
setting, including:
• Burden of disease and understanding of unmet need of the cervical population (clinical and non-clinical)
• Evolving treatment landscape including new clinical data and treatment sequencing
• Clinical management of patients being treated with novel therapies, such as ADCs
Oncology – Hematologic
Increase understanding in the following areas:
Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
• Risk mitigation and management of toxicities associated with antibody drug conjugates (ADCs)
• Improving outcomes on subsets of Acute Leukemia patients:
o ALL in relapsed / refractory setting by salvage status, MRD, Ph+, cytogenetics, transplant setting
o First line treatment landscape for AML patients eligible for intensive induction chemotherapy
o First line treatment landscape for AML patients ineligible for intensive induction chemotherapy
• Recent developments in 1L therapy for ALL/AML using novel agents (monotherapy, combination, sequencing, cellular/immuno
therapies)
• Future treatment landscape of ALL and AML especially exploring combination therapy with new novel oral agents
Chronic Myelogenous Leukemia (CML)
• The treatment/management of gastrointestinal toxicities and other commonly associated adverse events with TKIs
• Patient adherence strategies with the initiation and maintenance of TKI therapy
• Careful selection of patients for treatment discontinuation/use in real-world setting of treatment discontinuation
• Optimal dose initiation and maintenance of TKI choice based on patient’s medical history and comorbidities (e.g.,
cardiovascular risk factors)
• Evidence for TKI choice in first and later lines for CP-CML (1L, 2L, 3L, 4L)
• Future treatment landscape in CML specifically exploring combinations with novel therapies
Questions? Email GMGP@pfizer.com
Updated February 2025

2025
Pfizer Global Medical Grants & Partnerships
Annual Meetings: Submission Deadlines, Primary Areas of Interest, & Educational Goals
Hodgkin Lymphoma (HL)
Increase and maintain knowledge and competence of:
• long-term clinical efficacy and safety profile of existing 1L treatment options in early and advanced stage, and sequencing for
optimal patient outcomes in HL
• different treatment options for, and survivorship of, the pediatric and AYA patient population
• early identification of Adverse Events and management/resolution strategies across multiple lines of therapy in HL, including
monotherapy and combo therapy
• how improved long-term outcomes for patients w/HL can translate into reduction in holistic cost of care including productivity
and indirect costs
T-Cell Lymphoma
Increase and maintain awareness and knowledge regarding the:
• long-term clinical efficacy and safety profile of therapeutic options in the 1L treatment of PTCL across histologies
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Increase awareness and knowledge regarding:
• Diagnostic and prognostic biomarkers for DLBCL, and utility in guiding treatment decision-making and patient management
• Treatment options for patients with relapsed/refractory DLBCL, taking into consideration efficacy, safety, and patient-specific
factors, to optimize patient outcomes
• Management of adverse events associated with novel therapies used in the treatment of patients with relapsed/refractory DLBCL
Biomarker Driven approaches in Lymphoma
• Diagnosis, prognosis and treatment approaches based on biomarkers, including CD30, in lymphoma
• Mechanisms of drug-resistance/loss of response with approved and emerging treatments
Questions? Email GMGP@pfizer.com
Updated February 2025

2025
Pfizer Global Medical Grants & Partnerships
Annual Meetings: Submission Deadlines, Primary Areas of Interest, & Educational Goals
Multiple Myeloma
Increase healthcare professional understanding of BCMA-directed therapies (BCMAxCD3 bi-specifics; BCMA-ADC; BCMA – CAR-T cells)
in relapsed/refractory multiple myeloma, including:
• Mechanisms of action
• Available clinical data – efficacy insights and side effect profiles
• Scientific rationale for potential sequencing of therapies
• Use of predictive or prognostic biomarkers
• Role of sBCMA on this therapeutic class
• Therapy management
Oncology – Thoracic (including lung and head and neck cancer)
Increase the awareness and understanding of the importance of treating and managing patients with ALK and BRAF mutated advanced NSCLC,
including:
• Educating on the latest clinical updates, including efficacy and adverse event profiles
• Therapy management of ALK and/or BRAF targeted therapies
• Address educational gaps in community oncology in diagnosis, treatment and management of ALK and BRAF advanced NSCLC
• Provide education directly to patients on the importance of biomarker testing, active shared decision making, and AE management and support
throughout the lung cancer treatment journey
• The role of the multi-disciplinary team collaboration and coordination of care in the treatment and management during ALK or BRAF inhibitor
therapy
Educate the global thoracic cancer medical community about promising new targets and ADCs in development.
Oncology – Skin - Melanoma
Increase the understanding of MAPK pathway inhibitors and their use in the treatment of melanoma including:
• Mechanism of action of targeted therapy
• Incorporating BRAF biomarker and genomic testing into community practice
• Increasing understanding of recent clinical data to help inform the selection of treatment options
• Monitoring for and managing side effects of therapies
• Exploring the management of special population metastatic melanoma patients
Questions? Email GMGP@pfizer.com
Updated February 2025

2025
Pfizer Global Medical Grants & Partnerships
Rare Diseases
Annual Meetings: Submission Deadlines, Primary Areas of Interest, & Educational Goals
Hemophilia
Improve the care of patients by:
• Educating on the evolving treatment landscape (i.e. genetic medicine, rebalancing strategies) for hemophilia to improve the understanding
of these novel approaches and their potential clinical applicability.
• Discussing shared decision making (SDM) and practical approaches on how SDM can be incorporated into hemophilia patient care
• Sharing knowledge and best practices (i.e. staff training, SOP, follow-up care) on how Hemophilia Treatment Centers (HTCs) and
multidisciplinary team are preparing for novel therapies in development
• Advancing patient education on the evolving hemophilia treatment landscape and improving patient’s empowerment and ability to make
informed decisions about their care
CVM- ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Improve the care of patients by:
• Educating healthcare professionals to increase awareness of heart failure patients at risk for TTR Amyloidosis and enable
appropriate and early patient identification through an evidence-based approach.
• Increasing awareness of at risk and undiagnosed populations with TTR amyloidosis with a focus on improving systematic strategies
that facilitate the appropriate diagnosis of patients early in the disease course before overt cardiomyopathy has ensued [e.g.,
populations with electrical disturbances, valvular disease, orthopedic manifestations, and cardio-oncology diseases (i.e., Light Chain
Amyloidosis)].
• Increasing awareness of at risk and underdiagnosed minority and underserved populations with TTR amyloidosis including, but not
limited to, women, African Americans, Native Americans, Alaskan Natives.
• Establishing a call to action to raise awareness on ATTR-CM in women to reduce gender-based disparities and earlier patient
identification.
• Identifying significant barriers that contribute to geographic, gender and racial healthcare disparities disproportionately impacting
the hereditary ATTR-CM subtype patient population and addressing these challenges to increase earlier diagnosis and treatment.
• Addressing challenges to caring for heart failure patients during an era of increased telehealth utilization including continuity of
care, appropriate diagnoses, and support for the referral base needs of patients at risk for TTR amyloidosis.
• Increasing awareness of the changing epidemiology of TTR amyloidosis with a focus on the prevalence of hereditary ATTR-CM and
wild-type ATTR-CM subtypes as the science continues to evolve.
• Increasing awareness and understanding of the role of imaging in the early identification of patients with ATTR-CM and/or the role
of bone radiotracer scintigraphy as a non-invasive alternative for the appropriate diagnosis of TTR cardiac amyloidosis in select
patients.
• Exploring strategies that empower patients to play an active role in understanding TTR amyloidosis and decision making regarding
available diagnostic and disease management options.
Questions? Email GMGP@pfizer.com
Updated February 2025

2025
Pfizer Global Medical Grants & Partnerships
Annual Meetings: Submission Deadlines, Primary Areas of Interest, & Educational Goals
Health Equity
This category supports education of healthcare professionals and care teams that seeks to enlighten and inform so that health equity becomes part of
practice, process, action, innovation, and/or organizational performance and outcomes.
Clinical Areas Reviewed through Joint Alliances/Partnerships
Diabetes Treatment
Pfizer and Merck are working together on grants in support of diabetes treatment-related education. The goal of this education is to
increase the understanding of SGLT2 inhibition in the management of diabetes.
All grant applications should be submitted to Merck only. Please refer to the Merck website for information.
Oncology - Nonsteroidal Anti-Androgen Treatment of Prostate
In the United States, Pfizer and Astellas are working together on grants in support of prostate cancer-related education. The goal of this
education is to increase the ability of healthcare professionals to consistently provide their patients with optimal guidelines-based care.
All grant applications should be submitted to Astellas only. Please refer to the Astellas website for information.
Thrombosis Prevention / Anti-coagulation
Pfizer and Bristol Myers Squibb (BMS) are working together on grants in support of thrombosis / anticoagulation-related education. The goal of
this education is to decrease the unmet medical needs in the prevention and treatment of venous and arterial thrombosis.
All grant applications should be submitted to Bristol Myers Squibb only. Please refer to the Bristol Myers Squibb website for information.
Questions? Email GMGP@pfizer.com
Updated February 2025